ECSP18000042A - Compuestos inhibidores de la señalización de la vía de notch - Google Patents
Compuestos inhibidores de la señalización de la vía de notchInfo
- Publication number
- ECSP18000042A ECSP18000042A ECIEPI201842A ECPI201800042A ECSP18000042A EC SP18000042 A ECSP18000042 A EC SP18000042A EC IEPI201842 A ECIEPI201842 A EC IEPI201842A EC PI201800042 A ECPI201800042 A EC PI201800042A EC SP18000042 A ECSP18000042 A EC SP18000042A
- Authority
- EC
- Ecuador
- Prior art keywords
- notch
- inhibiting compounds
- way signaling
- pharmaceutically acceptable
- signaling inhibiting
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000011664 signaling Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 210000002266 hair cells auditory Anatomy 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010011891 Deafness neurosensory Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005650 Notch Receptors Human genes 0.000 abstract 1
- 108010070047 Notch Receptors Proteins 0.000 abstract 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 abstract 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención proporciona compuestos, o una sal farmacéuticamente aceptable de estos, y una composición farmacéutica que contiene dichos compuestos o una sal farmacéuticamente aceptable de esta, útil como un inhibidor de la señalización de la vía Notch para los cánceres nombrados, pérdida de audición neurosensorial causada por la pérdida de células ciliadas auditivas, e inducción de la generación de células ciliadas auditivas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189393P | 2015-07-07 | 2015-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP18000042A true ECSP18000042A (es) | 2018-03-31 |
Family
ID=56507825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201842A ECSP18000042A (es) | 2015-07-07 | 2018-01-02 | Compuestos inhibidores de la señalización de la vía de notch |
Country Status (42)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150209367A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| AR105080A1 (es) | 2015-07-07 | 2017-09-06 | Lilly Co Eli | Compuestos inhibidores de la señalización de la vía de notch |
| CA3029281A1 (en) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| US11253193B2 (en) * | 2016-11-08 | 2022-02-22 | Cochlear Limited | Utilization of vocal acoustic biomarkers for assistive listening device utilization |
| KR20190098998A (ko) | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
| TW201838989A (zh) * | 2017-03-24 | 2018-11-01 | 瑞士商諾華公司 | 異噁唑羧醯胺化合物及其用途 |
| US11117932B2 (en) * | 2018-07-20 | 2021-09-14 | The Hong Kong Polytechnic University | Peptides for specific inhibition of Jag 1-Notch 1 pathway |
| CR20210148A (es) * | 2018-09-21 | 2021-05-18 | Novartis Ag | Compuestos de isoxazol carboxamida y usos de los mismos |
| WO2020072602A1 (en) | 2018-10-02 | 2020-04-09 | Frequency Therapeutics, Inc. | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
| WO2020112883A1 (en) * | 2018-11-30 | 2020-06-04 | Massachusetts Eye And Ear Infirmary | Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells |
| CA3136424A1 (en) | 2019-04-08 | 2020-10-15 | Frequency Therapeutics, Inc. | Combination of chir99021 and valproic acid for treating hearing loss |
| WO2021150672A2 (en) * | 2020-01-22 | 2021-07-29 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for placenta accreta spectrum (pas) disorders |
| WO2022158610A1 (en) * | 2021-01-20 | 2022-07-28 | Prism BioLab Co., Ltd. | Novel bicyclic compounds |
| WO2023200017A1 (en) * | 2022-04-11 | 2023-10-19 | Prism BioLab Co., Ltd. | Novel seven-membered ring-fused compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
| MX2008012136A (es) | 2006-03-27 | 2008-10-03 | Hoffmann La Roche | Derivados de malonamida como inhibidores de gama secretasa. |
| EP2732819B1 (en) | 2008-02-07 | 2019-10-16 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh-1 expression |
| US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| AU2009316264B2 (en) | 2008-11-24 | 2016-09-15 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| WO2012047706A2 (en) | 2010-10-06 | 2012-04-12 | Massachusetts Eye & Ear Infirmary | Methods for promotiing reinnervation of auditory hair cells |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| US8716229B2 (en) | 2011-11-09 | 2014-05-06 | Massachusetts Eye & Ear Infirmary | Osteoprotegerin in neuroprotection |
| US20150209367A1 (en) * | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| EP2914724A1 (en) | 2012-11-02 | 2015-09-09 | Genesys Research Institute | Compositions and methods for auditory therapy |
| AR105080A1 (es) | 2015-07-07 | 2017-09-06 | Lilly Co Eli | Compuestos inhibidores de la señalización de la vía de notch |
| KR20190098998A (ko) * | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
-
2016
- 2016-06-21 AR ARP160101848A patent/AR105080A1/es active IP Right Grant
- 2016-06-21 TW TW105119456A patent/TWI625332B/zh active
- 2016-06-21 JO JOP/2016/0125A patent/JO3491B1/ar active
- 2016-07-01 AU AU2016289822A patent/AU2016289822B2/en active Active
- 2016-07-01 WO PCT/US2016/040612 patent/WO2017007702A1/en active Application Filing
- 2016-07-01 TN TNP/2017/000495A patent/TN2017000495A1/en unknown
- 2016-07-01 TR TR2019/08683T patent/TR201908683T4/tr unknown
- 2016-07-01 MX MX2017016555A patent/MX376082B/es active IP Right Grant
- 2016-07-01 ME MEP-2019-191A patent/ME03495B/me unknown
- 2016-07-01 MA MA42399A patent/MA42399B1/fr unknown
- 2016-07-01 MY MYPI2018700032A patent/MY197519A/en unknown
- 2016-07-01 LT LTEP16741742.7T patent/LT3319967T/lt unknown
- 2016-07-01 DK DK16741742.7T patent/DK3319967T3/da active
- 2016-07-01 US US15/736,345 patent/US10450317B2/en active Active
- 2016-07-01 UA UAA201712094A patent/UA120539C2/uk unknown
- 2016-07-01 PE PE2018000012A patent/PE20180412A1/es unknown
- 2016-07-01 CR CR20220368A patent/CR20220368A/es unknown
- 2016-07-01 ES ES16741742T patent/ES2735139T3/es active Active
- 2016-07-01 EA EA201792478A patent/EA032634B1/ru not_active IP Right Cessation
- 2016-07-01 JP JP2017568395A patent/JP6571214B2/ja active Active
- 2016-07-01 HU HUE16741742 patent/HUE044666T2/hu unknown
- 2016-07-01 CR CR20170598A patent/CR20170598A/es unknown
- 2016-07-01 PT PT16741742T patent/PT3319967T/pt unknown
- 2016-07-01 CN CN201680039699.XA patent/CN107849054B/zh active Active
- 2016-07-01 CA CA2987431A patent/CA2987431C/en active Active
- 2016-07-01 PL PL16741742T patent/PL3319967T3/pl unknown
- 2016-07-01 KR KR1020187000149A patent/KR102078946B1/ko active Active
- 2016-07-01 SI SI201630270T patent/SI3319967T1/sl unknown
- 2016-07-01 RS RS20190820A patent/RS59115B1/sr unknown
- 2016-07-01 EP EP16741742.7A patent/EP3319967B1/en active Active
- 2016-07-01 MD MDE20180506 patent/MD3319967T2/ro unknown
- 2016-07-01 NZ NZ737322A patent/NZ737322A/en unknown
-
2017
- 2017-11-16 IL IL255726A patent/IL255726B/en active IP Right Grant
- 2017-11-20 ZA ZA2017/07858A patent/ZA201707858B/en unknown
- 2017-12-20 SV SV2017005597A patent/SV2017005597A/es unknown
-
2018
- 2018-01-02 EC ECIEPI201842A patent/ECSP18000042A/es unknown
- 2018-01-02 CL CL2018000007A patent/CL2018000007A1/es unknown
- 2018-01-05 PH PH12018500047A patent/PH12018500047B1/en unknown
- 2018-01-05 DO DO2018000005A patent/DOP2018000005A/es unknown
- 2018-01-12 CO CONC2018/0000224A patent/CO2018000224A2/es unknown
- 2018-05-17 HK HK18106380.5A patent/HK1247187B/zh unknown
-
2019
- 2019-06-28 HR HRP20191175TT patent/HRP20191175T1/hr unknown
- 2019-07-23 CY CY20191100776T patent/CY1122024T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18000042A (es) | Compuestos inhibidores de la señalización de la vía de notch | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CO2018004750A2 (es) | Composiciones para inhibir la actividad arginasa | |
| MX392031B (es) | Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2 | |
| SV2016005180A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| GT201700189A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| ECSP17054980A (es) | Inhibidores selectivos de bace1 | |
| CL2018001067A1 (es) | Compuesto piranodipiridínico. | |
| MX2019010330A (es) | Formulaciones con mejora de la estabilidad. | |
| MX2016015106A (es) | Derivados de dipicolilamina y sus usos farmaceuticos. | |
| CL2018000489A1 (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
| EA201791596A1 (ru) | Пиразоловые соединения | |
| CU20140127A7 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| CR20160175A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| UA100342U (ru) | Применение натриевой соли гидрогенсульфида как средства для снижения гастротоксичности нестероидных противовоспалительных средств | |
| CO7141426A2 (es) | Moduladores de la ruta del complemento y usos de los mismos |